378
Participants
Start Date
February 28, 2006
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
rituximab [MabThera/Rituxan]
500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
rituximab [MabThera/Rituxan]
500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
rituximab [MabThera/Rituxan]
1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
Taoyuan District
Taichung
Diepkloof
Sydney
Coffs Harbour
Malvern
Melbourne
Eger
Debrecen
Southport
Maroochydore
Timaru
Cape Town
Christchurch
Ghent
Turin
Bangkok
Bangkok
Bangkok
Arenzano
Genoa
Dijon
Hamburg
León
Madrid
Madrid
Madrid
Bordeaux
Gijón
Montpellier
Valeggio sul Mincio
Khon Kaen
Ratingen
Seville
Reggio Emilia
Ferrara
Herne
Pieve di Coriano
Osnabrück
Chiang Mai
Cologne
Siena
Pisa
Lille
Prato
Bad Nauheim
Coppito
Heidelberg
Le Mans
Paris
Bois-Guillaume
Potenza
Palermo
Oulu
Beijing
Beijing
Goiânia
São Paulo
Penticton
Victoria
Winnipeg
London
Newmarket
Toronto
Trois-Rivières
Nice
Amsterdam
Leiden
Nijmegen
Auckland
Košice
Piešťany
Piešťany
Pretoria
Barcelona
Burgos
Kaohsiung City
Barnsley
Birmingham
Cambridge
Glasgow
London
Londonderry
Manchester
Metropolitan Borough of Wirral
Middlesbrough
Northampton
Nottingham
Reading
Truro
Wigan
Hoffmann-La Roche
INDUSTRY